Christian Buske

This study tests a drug called obinutuzumab in 56 people with newly diagnosed marginal zone lymphoma who cannot have or did not respond to local therapy. The goal is to see if this antibody can shrink tumors and control the disease without the harsh side effects of chemotherapy. …

This study tests whether adding carfilzomib to ibrutinib works better than ibrutinib alone for people with Waldenström's macroglobulinemia, a rare blood cancer. About 99 participants will receive either the combination or ibrutinib alone. The goal is to see if the combo leads to …

This study tests a chemotherapy-free combination of two drugs, Copanlisib and Rituximab, in 36 people with marginal zone lymphoma (MZL) who need treatment but cannot have or have failed local therapy. The goal is to see if this combo works as well as standard chemo but with fewer…

This study tests a chemotherapy-free combination of three drugs (bortezomib, rituximab, ibrutinib) in 53 people with newly diagnosed Waldenström's macroglobulinemia, a rare blood cancer. The goal is to see if this approach can control the disease for at least one year with fewer …